Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a Phase 3 study of the PI3Kδ inhibitor Zandelisib (ME-401) in combination with rituximab, in comparison to standard immunochemotherapy (Rituximab-Bendamustine or Rituximab-CHOP) in subjects with relapsed or refractory FL and MZL.
Epistemonikos ID: fb4f6540ce2b7157200e7f53d4f1b988d91944c4
First added on: May 08, 2024